Vaxart, Inc. (VXRT)
| Market Cap | 166.72M +63.4% |
| Revenue (ttm) | 255.61M +439.3% |
| Net Income | 37.10M |
| EPS | 0.16 |
| Shares Out | 241.72M |
| PE Ratio | 4.37 |
| Forward PE | 55.18 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 191,129 |
| Average Volume | 467,229 |
| Open | 0.6787 |
| Previous Close | 0.6800 |
| Day's Range | 0.6562 - 0.6900 |
| 52-Week Range | 0.2606 - 0.8449 |
| Beta | 1.18 |
| RSI | 45.32 |
| Earnings Date | May 7, 2026 |
About Vaxart
Vaxart, Inc., a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its vector-adjuvant-antigen standardized technology proprietary oral vaccine platform. The company’s product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; COVID-19 Vaccine, which is in Phase 2b clinical trial for the treatment of SARS-CoV-1, SARS-CoV-2, and Middle East respiratory syndrome coronavirus; Seasonal Influenza vaccine, which is... [Read more]
Financial Performance
Financial StatementsNews
Vaxart Earnings Call Transcript: Q1 2026
Q1 saw strong revenue growth and positive net income, driven by BARDA contracts and cost controls. Key clinical milestones for COVID-19 and norovirus programs are pending, with cash runway into Q2 2027 and flexible capital options in place.
Vaxart Provides Business Update and Reports First Quarter 2026 Financial Results
Topline data from 400-person sentinel cohort of the Phase 2b COVID-19 trial anticipated in Q2 2026 Cash, cash equivalents, and investments of $61.0 million as of March 31, 2026; runway into second qua...
Vaxart to Host Stockholder Fireside Chat on May 8 at 4:30 p.m. ET
Company to report first quarter 2026 financial results on May 7 SOUTH SAN FRANCISCO, Calif., May 01, 2026 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX: VXRT) today announced that members of the Company's s...
Vaxart Appoints James Breitmeyer, M.D., Ph.D., to Board of Directors
Appointment strengthens Board's clinical development and regulatory expertise as Vaxart advances its oral vaccine platform
Vaxart Announces Share Purchase Agreement for up to $25 Million with Lincoln Park Capital
SOUTH SAN FRANCISCO, Calif., April 17, 2026 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX: VXRT) (“Vaxart” or the “Company”), a clinical-stage biotechnology company developing a range of oral vaccines based...
Vaxart Transcript: Fireside chat
Management discussed progress on partnerships, clinical milestones, and cost-saving measures, emphasizing the oral vaccine platform's global potential and ongoing efforts to secure funding and partnerships. The team addressed delays, clarified operational changes, and outlined a cash runway into Q2 2027.
Vaxart Earnings Call Transcript: Q4 2025
Revenue surged to $237.3M in 2025, driven by BARDA and Dynavax deals, with cash runway into Q2 2027. Key COVID-19 and norovirus vaccine trials are progressing, with major data readouts expected in 2026 and significant milestone payments possible.
Vaxart to Host Upcoming Conference Calls
Full year 2025 business update and financial results conference call to be held March 12 at 4:30 p.m. ET Stockholder fireside chat to be held on March 13 at 4:30 p.m.
Vaxart Transcript: Oppenheimer 36th Annual Healthcare Life Sciences Conference
The oral pill vaccine platform offers both systemic and mucosal immunity, with ongoing phase IIb trials for COVID-19 and advanced programs in norovirus and influenza. Strategic partnerships, notably with Dynavax (now Sanofi), provide funding and validation, while upcoming data readouts and potential expansion into new indications are expected to drive growth.
Vaxart announces publication in npj Vaccines on norovirus candidate
Vaxart (VXRT) announced the publication in npj Vaccines of data from a double-blind, placebo-controlled Phase 1 trial evaluating a single-dose, oral bivalent vaccine candidate in post-partum, breastfe...
Vaxart Transcript: Global BioInnovation Forum 2026
Oral pill vaccines are being developed to improve convenience, access, and immune response, with strong preclinical and clinical data supporting efficacy and safety. Key COVID-19 and norovirus trial results are expected in 2026, potentially marking major milestones.
Vaxart to Participate in the Global BioInnovation Forum on January 13, 2026
SOUTH SAN FRANCISCO, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX: VXRT) (“Vaxart or “the Company”), a clinical-stage biotechnology company developing a range of oral recombinant pill vaccine...
Vaxart Earnings Call Transcript: Q3 2025
Secured a transformative partnership with Dynavax for the oral COVID-19 vaccine, extending cash runway into Q2 2027 and validating the platform. Q3 revenue surged to $72.4 million, and robust progress was made in both COVID-19 and norovirus programs.
Options Volatility and Implied Earnings Moves Today, November 13, 2025
Today, several major companies are expected to report earnings: Applied Materials (AMAT), Ballard Power Systems (BLDP), Walt Disney (DIS), JD (JD), Vaxart (VXRT), Virgin Galactic Holdings (SPCE), Lumi...
Dynavax enters license agreement for Vaxart’s oral COVID-19 vaccine program Vaxart
Dynavax Technologies (DVAX) and Vaxart (VXRT) announced that they have entered into an exclusive, worldwide license and collaboration agreement for Vaxart’s investigational oral COVID-19 vaccine candi...
Dynavax Reports Third Quarter 2025 Financial Results and Announces New $100 Million Share Repurchase Program
HEPLISAV-B® quarterly net product revenue of $90 million, a 13% YoY increase; r eiterates full year 2025 HEPLISAV-B® net product revenue guidance range of $315 to $325 million Board of Directors autho...
Dynavax Enters Exclusive License Agreement for Vaxart's Novel Oral COVID-19 Vaccine Program
Collaboration positioned to leverage Vaxart's oral vaccine platform and Dynavax's commercial experience to address the long-term need for easily administered COVID-19 vaccine options Vaxart to continu...
Vaxart to Showcase its Norovirus and COVID-19 Oral Pill Vaccine Candidates at World Vaccine Congress Europe 2025
SOUTH SAN FRANCISCO, Calif., Oct. 08, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX: VXRT) (“Vaxart” or the “Company”), a clinical-stage biotechnology company developing a range of oral recombinant pil...
Vaxart wthdraws reverse stock split proposal
Vaxart (VXRT) has withdrawn its reverse stock split proposal. “After careful consideration, we have decided to officially withdraw our reverse stock split proposal. Moving forward, we will continue to...
Vaxart shareholders reiterate intent to vote against reverse stock split
Richard John Burgess, Daniel Houle, Michael Patrick Kelley, Marc Eustace Pereira, Patrice Raffy, Benjamin Sauv, Mark Silverberg, Matthew Wallace and David Whitney, who collectively beneficially own mo...
Vaxart Appoints W. Mark Watson as Lead Independent Director
In process of adopting a Director stock ownership policy to reinforce commitment of aligning the Board's interests with stockholders
Vaxart Reports Additional Phase 1 Data Supporting the Potential Efficacy of its Second-Generation Norovirus Oral Pill Vaccine Candidate
- Second-generation constructs induce robust increases in fecal IgA, which was shown to be correlated with protection against infection in the company's previous Phase 2b challenge study -
Vaxart shareholders ‘condemn’ board decision to adjourn reverse stock split vote
Richard John Burgess, Daniel Houle, Michael Patrick Kelley, Marc Eustace Pereira, Patrice Raffy, Benjamin Sauv, Matthew Wallace, and David Whitney, who collectively beneficially own more than 2.5M sha...
Concerned Vaxart Stockholders Condemn Board's Decision to Adjourn Reverse Stock Split Vote at Special Meeting
Question Board's Repeated Delay Tactics and Demand Transparency on Voting Results, Nasdaq Compliance and Governance Changes
Vaxart Transcript: H.C. Wainwright 27th Annual Global Investment Conference
A thermally stable oral pill vaccine platform is advancing programs for norovirus, COVID-19, and flu, with significant clinical progress and upcoming milestones including a phase 2B norovirus study and a large COVID-19 trial. The platform aims to address unmet needs and provide alternatives to traditional vaccines.